{"entity":{"id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","aka":[],"tldr":"A phase 1/2 trial of retlirafusp alfa, rivoceranib (apatinib), gemcitabine and nab-paclitaxel in pancreatic cancer, run by West China Hospital, not yet recruiting.","summary":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC is a phase 1/2, interventional study registered as NCT07802184 by West China Hospital, with a registry enrolment figure of 45 participants, started 2026-09-10 and due to reach its primary completion in 2029-01-01. Interventions recorded: SHR-1701; Apatinib; gemcitabine; Nab-paclitaxel. Conditions listed: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer. Primary outcome: Recommended Phase II Dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"1\\) Age 18-75 years, regardless of sex; 2) patients with histologically confirmed pancreatic ductal adenocarcinoma (PDAC); 3) previously untreated patients with unresectable locally advanced or metastatic PDAC, with at least one measurable lesion according to RECIST v1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07802184","url":"https://clinicaltrials.gov/study/NCT07802184"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["retlirafusp-alfa","rivoceranib","gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07802184","phase":"1/2","setting":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center, Open-Label, Phase Ib/II Trial","sponsor":"West China Hospital","enrolled":45,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07802184/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}